MannKind CorpMNKD
Market Cap: $1.85B
About: MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Employees: 414
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
50% more funds holding in top 10
Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]
47% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $9.17M
22% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 27
16% more capital invested
Capital invested by funds: $622M [Q1] → $720M (+$98.5M) [Q2]
10% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 60
3% more funds holding
Funds holding: 199 [Q1] → 205 (+6) [Q2]
0.16% less ownership
Funds ownership: 50.78% [Q1] → 50.63% (-0.16%) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Leerink Partners Faisal Khurshid 100% 1-year accuracy 3 / 3 met price target | 19%upside $8 | Outperform Assumed | 9 Sept 2024 |
Oppenheimer Steven Lichtman 80% 1-year accuracy 4 / 5 met price target | 79%upside $12 | Outperform Maintained | 28 Aug 2024 |
Financial journalist opinion
Based on 3 articles about MNKD published over the past 30 days